Morgan Stanley raised the firm’s price target on Amwell (AMWL) to $6.50 from $6 and keeps an Equal Weight rating on the shares. Revenue upside in the quarter and tighter cost controls “mark a solid start to the year, admittedly against low investor expectations,” the analyst says in a post-earnings note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Amwell Maintains Hold as Analyst Lifts Price Target to $6.50 Amid Improving Metrics but Unproven Growth Recovery
- American Well Kept at Hold as Strong Q1 and Profit Progress Offset by Cautious Revenue Outlook and Government Contract Uncertainty
- American Well announces planned board transition for 2026